Avenor contains the long-acting beta agonist (LABA) salmeterol and the inhaled corticosteroid (ICS) fluticasone. It is indicated for regular treatment of asthma where use of a combination LABA/ICS is appropriate, in patients not adequately controlled with ICS and 'as needed' inhaled short-acting β2 agonist or those already adequately controlled on both ICS and LABA.
Three strengths of Avenor are available, providing a metered dose of 25 microgram salmeterol with fluticasone 50, 125 or 250 microgram (equivalent to a delivered dose of 23 microgram salmeterol with fluticasone 46, 115 or 230 microgram, respectively).
The lowest 25 microgram/50 microgram strength is licensed for use in children from the age of 4 years; the two higher strengths can be used in adults and adolescents from 12 years.
For patients who require a spacer for use with Avenor, AeroChamber Plus is the recommended device.